menu
    • menu
    [{"orgOrder":0,"company":"Hong Kong Winhealth Pharma Group","sponsor":"Merz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Amino Acid","year":"2021","type":"Collaboration","leadProduct":"L-Ornithine L-aspartate","moa":"Ammonia detoxification","graph1":"Neurology","graph2":"Approved FDF","graph3":"Hong Kong Winhealth Pharma Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hong Kong Winhealth Pharma Group \/ Hong Kong Winhealth Pharma Group","highestDevelopmentStatusID":"15","companyTruncated":"Hong Kong Winhealth Pharma Group \/ Hong Kong Winhealth Pharma Group"},{"orgOrder":0,"company":"Hong Kong Winhealth Pharma Group","sponsor":"TWi Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Diacerein","moa":"IL-1?","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Hong Kong Winhealth Pharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Hong Kong Winhealth Pharma Group \/ Hong Kong Winhealth Pharma Group","highestDevelopmentStatusID":"8","companyTruncated":"Hong Kong Winhealth Pharma Group \/ Hong Kong Winhealth Pharma Group"},{"orgOrder":0,"company":"Hong Kong Winhealth Pharma Group","sponsor":"Quoin Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Hong Kong Winhealth Pharma Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hong Kong Winhealth Pharma Group \/ Quoin Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Hong Kong Winhealth Pharma Group \/ Quoin Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Hong Kong Winhealth Pharma Group

    Menu

    Hong Kong Winhealth Pharma Group

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hong Kong Winhealth Pharma Group

                            Hong Kong arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Hong Kong Winhealth Pharma Group

                            Hong Kong arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QRX003

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : IND Enabling

                            Sponsor : Quoin Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Quoin Pharmaceuticals Announces Licensing and Distribution Agreement with Leading Rare Disease Company for Gre...

                            Details : The agreement will enable Quoin's pipeline product, QRX003, to provide healthcare professionals and patients in greater China, including Hong Kong, Macau and Taiwan, with access to its products upon receiving regulatory approval.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 15, 2022

                            Lead Product(s) : QRX003

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : IND Enabling

                            Sponsor : Quoin Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hong Kong Winhealth Pharma Group

                            Hong Kong arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Hong Kong Winhealth Pharma Group

                            Hong Kong arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : L-Ornithine L-aspartate

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Merz Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Winhealth Pharma and Merz Collaborate on Hepa-Merz® to benefit patients with liver disease in China

                            Details : The strategic cooperation between the two parties marks the obtainment of Winhealth Pharma for the exclusive commercial rights of Hepa-Merz® (L-ornithine L-aspartate, an important product under Merz' product portfolio) in China.

                            Product Name : Hepa-Merz

                            Product Type : Amino Acid

                            Upfront Cash : Undisclosed

                            March 08, 2021

                            Lead Product(s) : L-Ornithine L-aspartate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Merz Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Hong Kong Winhealth Pharma Group

                            Hong Kong arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Hong Kong Winhealth Pharma Group

                            Hong Kong arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diacerein

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Recipient : TWi Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Winhealth Pharma and TWiB Enter into Strategic Licensing Partnership on AC-203

                            Details : Strategic partnership grants Winhealth Pharma exclusive right to develop and commercialize rare disease asset AC-203 in mainland China, Hong Kong and Macao for indications including hereditary epidermolysis bullosa (EB), bullous pemphigoid and other skin...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 06, 2021

                            Lead Product(s) : Diacerein

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Recipient : TWi Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth